Abstract:High cancer heterogeneity and aggressiveness are major factors contributing to the poor prognosis of patients with advanced cancer1-5. Early detection of cancer can significantly improve the prognosis of patients with early-stage cancer after standard treatment. Although traditional cancer detection technologies, such as endoscopy for gastrointestinal cancer, mammography for breast cancer, HPV DNA detection for cervical cancer, and computed tomography and positron emission tomography-computed tomography, are effective, these largely non-invasive screening methods pose various challenges, including patient resistance due to discomfort during the procedures, high costs, and requirements for specialized equipment and experienced physicians. Consequently, conducting these procedures on a large scale is difficult. The emergence of circulating cell-free DNA (cfDNA), newly identified non-encapsulated DNA molecules, has revolutionized cancer early detection by offering a comprehensive genomic perspective. The abundant information contained in cfDNA includes mutations, copy number variations, gene fusions, DNA methylation, microbiome or virus-released nucleic acids, T cell receptor sequences, mitochondrial DNA abnormalities, fragment ratios, associated histone modifications, transcription start site (TSS) coverage, and promoter fragmentation entropy (PFE)6,7. (Figure 1). These innovative technologies have shown potential in accurate and practical approaches to large-scale cancer screening and preoperative evaluation. Although cfDNA-based technologies offer substantial promise for early cancer detection, they also have several limitations. For instance, clonal hematopoiesis leads to most cfDNA mutations, which can be confused with the mutations induced by the circulating tumor DNA, thereby affecting the accuracy of cancer diagnosis and the method's clinical utility. Additionally, mutated gene panels have low detection rates in patients with early-stage cancer8, and DNA methylation, although stable, cannot reflect cell-specific programs or molecular dynamics9. Moreover, the bisulfite processing of cfDNA results in degradation of at least 84%-96% of the DNA, thus leading to a loss of valuable information10. Consequently, samples of hundreds of nanograms (ng) of DNA (derived from 10 mL blood) are required to mitigate the effects of clonal hematopoiesis, rare counts in cfDNA mutations, and the substantial amount of degraded DNA in cfDNA methylation analyses. Although the limitations of some cfDNA-based technologies, including fragment ratio, associated histone modifications, TSS coverage, and PFE, are unclear, these signatures can be used to infer gene expression levels and chromatin accessibility status, thereby indicating the functional state of cancer cells, and providing comprehensive information on dynamic biological processes and heterogeneity during tumorigenesis, in contrast to approaches focusing on certain mutations and CpG islands. Hence, the enormous potential of these cfDNA-based technologies, including fragment ratio, associated histone modifications, TSS coverage, and PFE, warrant further in-depth exploration.

Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

Signatures Beyond Oncogenic Mutations in Cell-Free DNA Sequencing for Non-Invasive, Early Detection of Cancer

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Single-cell whole-genome sequencing reveals somatic mutation signatures in normal somatic cells predictive of cancer later in life

Detection and characterization of lung cancer using cell-free DNA fragmentomes

Genome-wide cell-free DNA fragmentation in patients with cancer

Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma

Whole genome DNA sequencing provides an atlas of somatic mutagenesis in healthy human cells and identifies a tumor-prone cell type

Analyzing somatic mutations by single-cell whole-genome sequencing

An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer

Noninvasive Detection of Chromosomal Instability in Plasma Circulating Cell-Free DNA for Early Pan-Cancer Diagnosis Using Low-Pass Whole-Genome Sequencing.

Detecting Somatic Mutations Without Matched Normal Samples Using Long Reads

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing

A computational framework to unify orthogonal information in DNA methylation and copy number aberrations in cell-free DNA for early cancer detection

Assessment of genome mutation analysis for tumor-informed detection of circulating tumor DNA in patients with breast cancer

Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer

Single-molecule detection of cancer mutations using a novel PCR-LDR-qPCR assay

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

Perspective on New Cell-Free DNA Technologies for Early Cancer Detection.

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma